<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2013072911676N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2013-10-09</date_registration>
      <primary_sponsor>Vice chancellor for Research, Tehran University of Medical Sciences and Health Services</primary_sponsor>
      <public_title>Effect of  midazolam-fentanyl versus propofol-ketamine sedation for peribulbar nerve block</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of midazolam-fentanyl versus propofol-ketamine sedation for peribulbar nerve block</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2013-08-13</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>70</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/11847</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Sedation in peribulbar block cataract surgery.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group (group pk): A minidose of lidocaine (10mg) for local anesthesia of  the vein endothelium was injected through the Intravenous catheter 1 min before the injection of propofol. The assigned study drug was administered in the dose of 0.03 mL/kg (maximum 2.5  mL) as a bolus. Additional study drug was then administered in 0.5-mL increments 15 s apart until the patients’ eyes closed and they were unresponsive to the verbal command “open your eyes.” The volume of study drug administered up to this point was termed the “hypnotic dose.” Hypnotic dose and supplemental dose of the study drug were recorded. If the patient exhibited grimacing and/or extremity movement requiring restraint, further needle insertion was withheld. Supplemental study drug was then administered in 0.5- to 1 mL increments at 10- s intervals until little or no patient movement and/or grimacing occurred with the advancement of the needle.(max dose 5 ml ). Intervention 2: Control group(group mf):The patients&#13;
   received either 1 microg/kg of&#13;
fentanyl and 0.02 mg/kg of midazolam by bolus IV injection 1 minute before&#13;
the administration of a PRBB.&#13;
  At the discretion of the anesthesiologist, intraoperative sedation consisting of 1-mL increments of the study drug or 0.5-mL increments of midazolam ( 1 mg/mL; maximal dose 2 mg) or fentanyl (50 mg/ mL; maximal dose 2 mL) could be administered to keep the patient comfortable but awake and responsive.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Abbas Ostadalipour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Farabi hospital, Tehran University of Medical Sciences</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1336616351</zip>
        <telephone>+98 21 5541 4104</telephone>
        <email>a-ostadalipour@tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sceinces</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Abbas Ostadalipour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Farabi hospital, Tehran University of Medical Sciences</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1336616351</zip>
        <telephone>+98 21 5541 4104</telephone>
        <email>a-ostadalipour@tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sceinces</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion creteria: ASA 1-3; patients older than 60 yr of age (max 80 yr) undergoing cataract extraction and intraocular lens implantation on an ambulatory surgery. &#13;
Patients were excluded if: they weighed  150% of their ideal body weight; had ischemic heart disease; had uncontrolled hypertension (systolic/diastolic blood pressure 180/ 110 mm Hg) or had a history of allergy to ketamine, propofol, or local anesthetic drugs; had a history of psychiatric disorders; suffered memory or cognitive dysfunction; had ingested a opoids, tranquilizer or psychoactive drug within 2 wk of surgery.</inclusion_criteria>
      <agemin>60 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>H25.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Senile cataract, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group (group pk): A minidose of lidocaine (10mg) for local anesthesia of  the vein endothelium was injected through the Intravenous catheter 1 min before the injection of propofol. The assigned study drug was administered in the dose of 0.03 mL/kg (maximum 2.5  mL) as a bolus. Additional study drug was then administered in 0.5-mL increments 15 s apart until the patients’ eyes closed and they were unresponsive to the verbal command “open your eyes.” The volume of study drug administered up to this point was termed the “hypnotic dose.” Hypnotic dose and supplemental dose of the study drug were recorded. If the patient exhibited grimacing and/or extremity movement requiring restraint, further needle insertion was withheld. Supplemental study drug was then administered in 0.5- to 1 mL increments at 10- s intervals until little or no patient movement and/or grimacing occurred with the advancement of the needle.(max dose 5 ml ).</i_keyword>
      <i_keyword>Control group(group mf):The patients&#13;
   received either 1 microg/kg of&#13;
fentanyl and 0.02 mg/kg of midazolam by bolus IV injection 1 minute before&#13;
the administration of a PRBB.&#13;
  At the discretion of the anesthesiologist, intraoperative sedation consisting of 1-mL increments of the study drug or 0.5-mL increments of midazolam ( 1 mg/mL; maximal dose 2 mg) or fentanyl (50 mg/ mL; maximal dose 2 mL) could be administered to keep the patient comfortable but awake and responsive</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Patient satisfaction. Timepoint: 3 to 5 min after injection. Method of measurement: Question.</prim_outcome>
      <prim_outcome>Quality of sedation. Timepoint: During injection. Method of measurement: Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Hemodynamic (systolic, diastolic and mean BP, heart rate). Timepoint: 1 min after sedation and 3 min after injection. Method of measurement: Automated hemodynamic monitoring , electrocardiogram.</sec_outcome>
      <sec_outcome>Spo2. Timepoint: 1-min after sedation and at 3 min after injection PBB. Method of measurement: Pulse oximeter.</sec_outcome>
      <sec_outcome>Degree of respiratory depression. Timepoint: 1-min after sedation and at 3 min after injection PBB. Method of measurement: Table of score.</sec_outcome>
      <sec_outcome>Air way intervention. Timepoint: 1-min after sedation and at 3 min after injection PBB. Method of measurement: Table of score.</sec_outcome>
      <sec_outcome>Side effects of drugs. Timepoint: During operation. Method of measurement: Record.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice chancellor for Research, Tehran University of Medical Sciences and Health Services</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2013-03-14</approval_date>
        <contact_name>Eye Research Center of Tehran university medical sceince</contact_name>
        <contact_address>Farabi hospital,Qazvin squer, south karegar Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
